Heart & Circulation

Cardiovascular Risk Assessment: Beyond Cholesterol and Risk Scores

How heart disease risk is assessed today, and why newer tools like CAC, ApoB, and Lp(a) are changing prevention.

3 min read

Intro

Cardiovascular risk assessment estimates your chance of having a heart attack or stroke.

Traditionally, this has relied on risk calculators using age, cholesterol, blood pressure, and smoking status.

But newer evidence shows these models can miss important individual risk—especially in people classified as “low” or “intermediate” risk.

Key Points

  • Risk calculators are a starting point—not a final answer
  • Many cardiovascular events occur in people labeled “low risk”
  • Coronary artery calcium (CAC) scoring improves risk prediction
  • ApoB and lipoprotein(a) provide deeper insight than standard cholesterol
  • Prevention is shifting toward earlier, more personalised assessment

Background

Most guidelines use tools such as:

  • Framingham Risk Score
  • ASCVD Risk Estimator

These calculate 10-year cardiovascular risk based on population data.

While useful, they average risk across large groups—meaning individual variation can be missed.

🚨 Breakout: The Hidden Risk Problem

Key insight: Many people who experience heart attacks were previously classified as low or intermediate risk.

Risk calculators estimate probability—not certainty.

They do not measure actual disease.

Causes and Mechanisms

Atherosclerosis develops over decades.

Key drivers include:

  • ApoB-containing lipoproteins
  • Inflammation
  • Genetic risk (e.g. elevated Lp(a))
  • Metabolic factors (insulin resistance, obesity)

Traditional cholesterol tests (LDL-C) do not fully capture this risk.

Modern Risk Tools

Coronary Artery Calcium (CAC)

A CT scan that detects calcified plaque in coronary arteries.

  • Score of 0 → low short-term risk
  • Higher scores → increasing risk

🚨 Breakout: Why CAC Matters

CAC is one of the strongest predictors of future heart events.

It directly measures disease—not just risk factors.

Apolipoprotein B (ApoB)

Measures the number of atherogenic particles.

  • More accurate than LDL-C in many patients
  • Strong predictor of cardiovascular risk

Lipoprotein(a) — Lp(a)

A genetically determined risk factor.

  • Not captured in standard cholesterol tests
  • Associated with premature cardiovascular disease

Diagnosis / Risk Stratification

A modern approach often combines:

  1. Risk calculator (baseline)
  2. Biomarkers (ApoB, Lp(a))
  3. Imaging (CAC in selected patients)

This allows more precise classification:

  • Truly low risk
  • Intermediate (uncertain)
  • High risk (early intervention warranted)

Risks / Benefits / Prognosis

Benefits of improved assessment

  • Earlier detection of disease
  • Better targeting of treatment
  • Avoids overtreatment in low-risk individuals

Limitations

  • Cost and access (e.g. CAC scans)
  • Not all patients require advanced testing

FAQ

Q: Who should consider a CAC scan?
A: Adults with borderline or intermediate risk where treatment decisions are uncertain.

Q: Is ApoB better than LDL cholesterol?
A: In many cases, yes—it reflects particle number rather than cholesterol content.

Q: Should everyone test Lp(a)?
A: Many guidelines recommend at least one lifetime measurement.

Q: Does a CAC score of 0 mean no risk?
A: It indicates low short-term risk, but not zero lifetime risk.

Q: Are risk calculators outdated?
A: No—but they should be combined with newer tools for better accuracy.

Further Reading